| Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging K Chang, HX Bai, H Zhou, C Su, WL Bi, E Agbodza, VK Kavouridis, ... Clinical Cancer Research 24 (5), 1073-1081, 2018 | 374 | 2018 |
| Effective treatment of low-risk acute GVHD with itacitinib monotherapy A Etra, A Capellini, A Alousi, MM Al Malki, H Choe, Z DeFilipp, WJ Hogan, ... Blood 141 (5), 481-489, 2023 | 19 | 2023 |
| The functional hallmarks of cancer predisposition genes A Capellini, M Williams, K Onel, KL Huang Cancer Management and Research, 4351-4357, 2021 | 11 | 2021 |
| Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease MM Al Malki, K London, J Baez, Y Akahoshi, WJ Hogan, A Etra, H Choe, ... Blood Advances 7 (17), 5189-5198, 2023 | 7 | 2023 |
| The success of behavioral economics in improving patient retention within an intensive primary care practice P Groden, A Capellini, E Levine, A Wajnberg, M Duenas, S Sow, B Ortega, ... BMC Family Practice 22 (1), 253, 2021 | 3 | 2021 |
| A day 14 endpoint for acute GVHD clinical trials N Spyrou, Y Akahoshi, S Kowalyk, G Morales, R Beheshti, ... Transplantation and Cellular Therapy 30 (4), 421-432, 2024 | 2 | 2024 |
| A Day 14 Endpoint for Acute Gvhd Clinical Trials N Spyrou, Y Akahoshi, S Kowalyk, G Morales, R Beheshti, ... Blood 142, 779, 2023 | | 2023 |
| AN EARLY ENDPOINT FOR ACUTE GRAFT VERSUS HOST DISEASE CLINICAL TRIALS N Spyrou, Y Akahoshi, S Kowalyk, G Morales, R Beheshti, J Portelli, ... BONE MARROW TRANSPLANTATION 58 (SUPP 1), 14-15, 2023 | | 2023 |
| Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy A Capellini, A Etra, AM Alousi, MM Al Malki, H Choe, Z Defilipp, ... Blood 140 (Supplement 1), 1867-1869, 2022 | | 2022 |
| Residual Convolutional Neural Network For Determination of IDH Status in Low-and High-Grade Gliomas K Chang, H Bai, I Ly, C Su, E Agbodza, V Kavouridis, J Senders, A Beers, ... SNO 2017 Annual Meeting, 2017 | | 2017 |
